Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Funko Inc (FNKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Funko Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Funko Inc trades at $5.48 (market cap $311.58M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 128× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FNKO | |
|---|---|---|
Market Cap | $39.89B | $311.58M |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $5.88 |
52-Week Low | $278.09 | $2.46 |
Enterprise Value | $38.15B | $556.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FNKO trades at $5.58, up 3.91% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with revenue declining to $908M in 2025 and a net loss of $67M, though recent quarters beat EPS estimates. Analyst consensus is divided with 42.9% buy ratings, while positive news includes new product launches and Q1 2026 revenue growth to $200.9M. Cash flow improved to a net positive $7.5M in 2025 from negative trends in prior years.
Outlook remains cautious due to persistent losses and high debt, but recent execution improvements and product innovation offer potential upside. Key risks include margin pressure and competitive threats in the collectibles market. Investors should weigh the bullish analyst sentiment against fundamental challenges before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
